SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs (India) informs about outcome of board meeting

10 May 2017 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulations 2015, Kilitch Drugs (India) has informed that Board of Directors in their meeting held on May 9, 2017 had approved the change in designation of Syed Azizur Rahman from Non-executive Director to Executive Director (Whole Time Director) of the company with effect from May 9, 2017.

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

159.95 5.90 (3.83%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×